Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.10
- Piotroski Score 1.00
- Grade N/A
- Symbol (CPHI)
- Company China Pharma Holdings, Inc.
- Price $0.19
- Changes Percentage (-2.51%)
- Change -$0.01
- Day Low $0.19
- Day High $0.20
- Year High $1.15
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -0.29
- Forward P/E Ratio -0.29
- P/E Growth -0.29
- Net Income $-3,078,818
Income Statement
Quarterly
Annual
Latest News of CPHI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CPHI Milan: Targeting supply chain bottlenecks key for cell and gene therapies
Angela Vollstedt, Global Director of Cell & Gene Therapies at Novartis, highlighted the potential of cell therapies to cure diseases at CPHI Europe....
By Yahoo! Finance | 1 month ago -
CPHI Europe: Gummies as a drug delivery system could improve compliance
Gummies are gaining popularity as a drug delivery system due to their taste, ease of consumption, and high compliance rates. Challenges include manufacturing complexity and maintaining stability. The ...
By Yahoo! Finance | 1 month ago -
What's the fight over McPhillamys goldmine about and why has Tanya Plibersek hit out at 'misinformation'?
A proposed goldmine near Blayney, NSW faces uncertainty as a federal decision blocks construction of a waste dam near an important Aboriginal site. The project's future hinges on additional approvals ...
By The Guardian | 2 months ago
